CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
|Name||Chg %||Market Cap|
|Eli Lilly & Co.||$212.37B|
|Madrigal Pharmaceuticals Inc.||$1.7B|
|Bristol Myers Squibb Co.||$147.31B|
|Novartis AG ADR||$210.32B|
|Teva Pharmaceutical Industries Ltd. ADR||$11.3B|
|Baxter International Inc.||$40.9B|